Business Wire

NY-PHILIP-MORRIS-INTL

Share
Swedish Match USA, Inc. Presents to U.S. Food and Drug Administration Advisory Committee to Renew Modified Risk Claim for General Snus

Experts from Swedish Match USA, Inc., an affiliate of Philip Morris International Inc. (NYSE: PM) (PMI), presented to the Tobacco Products Scientific Advisory Committee (TPSAC) on June 26, 2024. The committee, comprised of independent scientific researchers, provides regulatory guidance to the U.S. Food and Drug Administration’s (FDA) Center for Tobacco Products.

The half-day meeting was part of the FDA’s review of Swedish Match’s request to continue marketing General Snus products in the U.S. as Modified Risk Tobacco Products (MRTPs), and to expand permitted use of the reduced risk claim to reach, and transition, more legal-age smokers away from cigarettes.

Initially granted by FDA in October 2019, Swedish Match can communicate to legal age consumers that “Using General Snus instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” Currently that message is accessible only on the General Snus website.

Swedish Match presented to the committee real-world evidence showing the claim is delivering on its promise to reduce harm to individual tobacco users and benefit the health of the population and should be renewed.

In its renewal submission, Swedish Match is seeking to expand use to additional lawful marketing channels, such as point-of-sale display and direct mail to age-verified consumers.

As FDA’s Center for Tobacco Products Director Brian King said when unveiling its new five-year strategic plan, this is a critical moment in the history of tobacco product regulation,” Gerry Roerty, General Counsel for Swedish Match, USA, Inc. said to committee members. The Center’s mission is to make smoking-related disease and death a part of America’s past and “today, together, we can meaningfully advance that goal,” Roerty told committee members.

During the meeting, representatives from Swedish Match and committee members discussed a range of scientific, technical, and consumer-communications topics. The company provided an overview of its responsible marketing practices and presented evidence and research demonstrating low levels of use by unintended populations.

General Snus is a smokeless tobacco product, traditionally produced in Sweden, that is non-fermented, and air cured. The modified risk products submitted for renewal include eight General Snus varieties that have been made available in the U.S. for more than a decade, and include:

  • General Snus Original (pouch)
  • General Snus Original (loose)
  • General Snus White (pouch)
  • General Snus Mint (pouch)
  • General Snus Wintergreen (pouch)
  • General Snus Mini Mint (pouch)
  • General Snus Classic Blend (pouch)
  • General Snus Nordic Mint (pouch)

Stacey Kennedy, President, Americas Region & CEO of PMI’s U.S. business said: “We are understandably proud of our commitment to a cigarette-free America, which is achievable much faster if policy is guided by science.” She continued, “America’s 28 million adult smokers have been bombarded with misinformation about smoke-free products, which can cause confusion and prolong the most harmful form of nicotine consumption—smoking. We look forward to continuing dialogue with the FDA as it continues to consider renewal of this modified risk authorization.”

In 2022, PMI acquired Swedish Match – a leader in oral nicotine delivery – creating a global smoke-free champion. Our ambition is that all those who would otherwise continue smoking abandon cigarettes and switch completely to scientifically substantiated smoke-free products as soon as possible. Regulatory policies and decisions can accelerate the speed and magnitude of this historic change.

Since 2008, PMI has invested over $12.5 billion to develop, scientifically substantiate, and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of ending the sale of cigarettes.

Note to the editor

The General Snus products were first authorized as “appropriate for the protection of the public health” through the premarket tobacco product application process in 2015 following a PMTA submission earlier in that same year.

Since then, Swedish Match USA, Inc., has submitted eight annual reports over as many years, the last four of which were combined with MRTP annual reporting.

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is a leading international tobacco company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, PMI has invested over $12.5 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In 2022, PMI acquired Swedish Match – a leader in oral nicotine delivery – creating a global smoke-free champion led by the companies’ IQOS and ZYN brands. The U.S. Food and Drug Administration has authorized versions of PMI’s IQOS devices and consumables and Swedish Match’s General Snus as Modified Risk Tobacco Products. As of December 31, 2023, PMI's smoke-free products were available for sale in 84 markets, and PMI estimates that approximately 33 million adults around the world use PMI's smoke-free products. Smoke-free business accounted for approximately 37% of PMI’s total full-year 2023 net revenues. With a strong foundation and significant expertise in life sciences, PMI announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma business, aims to enhance life through the delivery of seamless health experiences. For more information, please visit www.pmi.com and www.pmiscience.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240701485978/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EADV 2025: Almirall Advances Skin Science and Leads Innovation for Holistic Patient Care in Medical Dermatology17.9.2025 08:57:00 CEST | Press release

Almirall’s scientific presence at the 34th EADV congress reflects its broad portfolio of dermatological treatments and patient-centric approach - featuring 44 abstracts, two expert-led symposia on atopic dermatitis and psoriasis, and an interactive booth. Lebrikizumab’s effectiveness in the treatment of moderate-to-severe atopic dermatitis is demonstrated by new real-world evidence, and long-term efficacy and patient well-being data. New real-world data demonstrate tildrakizumab’s effectiveness in the treatment of psoriasis in high-impact areas of the body and across multiple patient groups - particularly elderly patients and those with high disease burden. Almirall’s pipeline progress includes new initial phase 1 data on a developmental treatment for Hidradenitis Suppurativa (HS), LAD191 a monoclonal antibody targeting the Interleukin-1 Receptor Accessory Protein (IL-1RAP) shows preliminary signs of clinical symptom improvements, and a favourable safety and tolerability profile. Almir

SES delivered unprecedented MEO satellite connectivity for French Navy’s Clemenceau 25 mission17.9.2025 08:50:00 CEST | Press release

During international operations, SES’s high-throughput low-latency Medium Earth Orbit (MEO) managed satcom service provided connectivity to flagship aircraft carrier Charles de Gaulle of the French Carrier Strike Group (GAN) SES announced today that the French Navy’s aircraft carrier Charles de Gaulle leveraged its secure and reliable O3b mPOWER satcom service – Managed Naval mPOWERED – during the Clemenceau 25 mission. This high-throughput, low-latency Medium Earth Orbit (MEO) connectivity solution supported all of the aircraft carrier’s operations, while facilitating collaboration with mission partners. During the five-month deployment, the French Carrier Strike Group (GAN) covered 40,000 nautical miles and conducted various exercises and joint activities with around twenty allied nations. The connectivity provided by SES ensured optimal performance and uninterrupted operational availability for the aircraft carrier’s mission-critical applications. Thanks to the global reach, reliabi

Deepfakes Already Hitting Businesses as Often as Traditional Fraud, Regula Survey Finds17.9.2025 08:00:00 CEST | Press release

Fresh survey data from Regula, a global developer of identity verification (IDV) solutions and forensic devices, shows that the line between traditional fraud and impersonation attacks has vanished. Identity spoofing, biometric fraud, and AI-powered deepfakes have already struck one in three organizations worldwide, catching up with long-standing fraud tactics like forged documents and social engineering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916314726/en/ Regula’s survey shows that impersonation attacks overtake traditional fraud schemes. Three impersonation-driven tactics now dominate the fraud playbook, each exploiting weaknesses in verification: Identity spoofing (reported by 34% of organizations) — Holding up a printed photo, replaying a video, or showing a screen image to a camera. Often used to mass-open accounts for scams or mule networks. Biometric fraud (34%) — Physical deceptions like fake fingerprints

Overture Life Launches European Preorder Waitlist for DaVitri, the World’s First Microfluidics-Based Automated Vitrification Platform17.9.2025 07:00:00 CEST | Press release

Ahead of receipt of anticipated CE Mark, European customers can begin requesting DaVitri to expand patient access to high-quality IVF Overture Life, the innovator modernizing IVF to optimize reproductive freedom, today announced the launch of its European preorder waitlist for DaVitri, the world’s first automated vitrification platform. The waitlist ensures in vitro fertilization (IVF) facilities will be among the first in Europe to harness DaVitri to reduce manual workloads for their embryologists while eliminating operator variability, thereby providing patients with faster, more consistent procedures. As infertility rates spike worldwide, interest in egg freezing continues to rise while the infrastructure to support it lags behind. Egg freezing requires vitrification, typically a time-intensive, manual process vulnerable to human error that can only be performed by extensively trained embryologists. This has resulted in variability in egg and embryo survival rates that directly impa

Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 202517.9.2025 07:00:00 CEST | Press release

Across both STOP-HS1 and STOP-HS2, povorcitinib treatment resulted in continued clinically meaningful and statistically significant improvements for patients with active moderate to severe hidradenitis suppurativa (HS) through Week 24At Week 24, nearly 60% of efficacy-evaluable patients among both povorcitinib treatment groups achieved HiSCR50Additionally, patients treated with povorcitinib achieved HiSCR75 (31.0%-40.3%), HiSCR90 (13.8%-27.7%) and HiSCR100 (9.2%-21.3%) through Week 24Povorcitinib-treated patients also achieved greater improvements in skin pain by the first visit (Week 3) through Week 24 with 62%-70% achieving mild or no pain at Week 24 Incyte (Nasdaq:INCY) today announced new 24-week interim data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). These data will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye